CRISPR Therapeutics AG Shareholders' Equity for the year ending December 31, 2023: USD 1.88 B

CRISPR Therapeutics AG Shareholders' Equity is USD 1.88 B for the year ending December 31, 2023, a 0.39% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • CRISPR Therapeutics AG Shareholders' Equity for the year ending December 31, 2022 was USD 1.88 B, a -21.84% change year over year.
  • CRISPR Therapeutics AG Shareholders' Equity for the year ending December 31, 2021 was USD 2.40 B, a 44.18% change year over year.
  • CRISPR Therapeutics AG Shareholders' Equity for the year ending December 31, 2020 was USD 1.66 B, a 77.15% change year over year.
  • CRISPR Therapeutics AG Shareholders' Equity for the year ending December 31, 2019 was USD 939.42 M.
Key Data
Date Shareholders' Equity Cash and Short-Term Investments Receivables Inventory